GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Vineet Laboratories Ltd (BOM:543298) » Definitions » Debt-to-EBITDA

Vineet Laboratories (BOM:543298) Debt-to-EBITDA : 0.00 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Vineet Laboratories Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Vineet Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Vineet Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Vineet Laboratories's annualized EBITDA for the quarter that ended in Dec. 2023 was ₹-25 Mil. Vineet Laboratories's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Vineet Laboratories's Debt-to-EBITDA or its related term are showing as below:

BOM:543298' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.32   Med: 2.39   Max: 4.54
Current: 4.54

During the past 7 years, the highest Debt-to-EBITDA Ratio of Vineet Laboratories was 4.54. The lowest was 2.32. And the median was 2.39.

BOM:543298's Debt-to-EBITDA is ranked worse than
71.43% of 1218 companies
in the Chemicals industry
Industry Median: 2.29 vs BOM:543298: 4.54

Vineet Laboratories Debt-to-EBITDA Historical Data

The historical data trend for Vineet Laboratories's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vineet Laboratories Debt-to-EBITDA Chart

Vineet Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-EBITDA
Get a 7-Day Free Trial N/A - 2.32 2.39 4.40

Vineet Laboratories Quarterly Data
Mar17 Mar18 Mar19 Mar20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.02 1.52 27.14 2.43 -

Competitive Comparison of Vineet Laboratories's Debt-to-EBITDA

For the Chemicals subindustry, Vineet Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vineet Laboratories's Debt-to-EBITDA Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Vineet Laboratories's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Vineet Laboratories's Debt-to-EBITDA falls into.



Vineet Laboratories Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Vineet Laboratories's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(262.409 + 48.479) / 70.609
=4.40

Vineet Laboratories's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -25.16
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Vineet Laboratories  (BOM:543298) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Vineet Laboratories Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Vineet Laboratories's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Vineet Laboratories (BOM:543298) Business Description

Traded in Other Exchanges
Address
5-5-160, Malleswari Nilayam, Opposite Vishnu Theatre, Chintalakunta, L.B.Nagar, Hyderabad, TG, IND, 500 074
Vineet Laboratories Ltd Formerly known as Ortin Laboratories Limited, Unit-II is engaged in the business of Pharmaceutical intermediates and Fine chemicals. The products of the companies include Dimethyl phenoxy acetyl chloride, Dimethyl Phenoxy Acetic Acid, Isopropyl-beta-D-thiogalactopyranoside and Nitrophenyl phosphate disodium salt among others. Geographically, the company operates within India and outside India, with a majority of revenue coming from India. The company has one business segment, manufacture of Drug Intermediates & Bulk Dugs.

Vineet Laboratories (BOM:543298) Headlines

No Headlines